Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2
Corinne Pellieux, … , Hans-R. Brunner, Thierry Pedrazzini
Corinne Pellieux, … , Hans-R. Brunner, Thierry Pedrazzini
Published December 15, 2001
Citation Information: J Clin Invest. 2001;108(12):1843-1851. https://doi.org/10.1172/JCI13627.
View: Text | PDF
Article

Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2

  • Text
  • PDF
Abstract

FGF-2 has been implicated in the cardiac response to hypertrophic stimuli. Angiotensin II (Ang II) contributes to maintain elevated blood pressure in hypertensive individuals and exerts direct trophic effects on cardiac cells. However, the role of FGF-2 in Ang II–induced cardiac hypertrophy has not been established. Therefore, mice deficient in FGF-2 expression were studied using a model of Ang II–dependent hypertension and cardiac hypertrophy. Echocardiographic measurements show the presence of dilated cardiomyopathy in normotensive mice lacking FGF-2. Moreover, hypertensive mice without FGF-2 developed no compensatory cardiac hypertrophy. In wild-type mice, hypertrophy was associated with a stimulation of the c-Jun N-terminal kinase, the extracellular signal regulated kinase, and the p38 kinase pathways. In contrast, mitogen-activated protein kinase (MAPK) activation was markedly attenuated in FGF-2–deficient mice. In vitro, FGF-2 of fibroblast origin was demonstrated to be essential in the paracrine stimulation of MAPK activation in cardiomyocytes. Indeed, fibroblasts lacking FGF-2 expression have a defective capacity for releasing growth factors to induce hypertrophic responses in cardiomyocytes. Therefore, these results identify the cardiac fibroblast population as a primary integrator of hypertrophic stimuli in the heart, and suggest that FGF-2 is a crucial mediator of cardiac hypertrophy via autocrine/paracrine actions on cardiac cells.

Authors

Corinne Pellieux, Alessandro Foletti, Giovanni Peduto, Jean-François Aubert, Jürg Nussberger, Friedrich Beermann, Hans-R. Brunner, Thierry Pedrazzini

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2018 2017 2016 2015 2014 2013 2011 2010 2009 2008 2007 2006 2005 2002 Total
Citations: 2 4 2 2 4 7 3 6 3 1 4 3 1 2 5 2 1 2 1 55
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (55)

Title and authors Publication Year
Serum fibroblast growth factor-2 levels complement vital biomarkers for diagnosing heart failure
Yu ZL, Cai ZH, Zheng JT, Jiang HY, Zhou YQ, Wong NK, Fu HB, Hong XB
BMC Cardiovascular Disorders 2024
FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy.
Campos I, Richter B, Thomas SM, Czaya B, Yanucil C, Kentrup D, Fajol A, Li Q, Secor SM, Faul C
Journal of cardiovascular development and disease 2024
Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis
Bertaud A, Joshkon A, Heim X, Bachelier R, Bardin N, Leroyer AS, Blot-Chabaud M
International journal of molecular sciences 2023
Distinct mononuclear diploid cardiac subpopulation with minimal cell-cell communications persists in embryonic and adult mammalian heart.
Zhu M, Liang H, Zhang Z, Jiang H, Pu J, Hang X, Zhou Q, Xiang J, He X
Frontiers of Medicine 2023
The Microenvironment of the Pathogenesis of Cardiac Hypertrophy
Bazgir F, Nau J, Nakhaei-Rad S, Amin E, Wolf MJ, Saucerman JJ, Lorenz K, Ahmadian MR
Cells 2023
Fibroblast Growth Factor 2
Nickle A, Ko S, Merrill AE
Differentiation; research in biological diversity 2023
A Comprehensive Outlook on Dilated Cardiomyopathy (DCM): State-Of-The-Art Developments with Special Emphasis on OMICS-Based Approaches
Sarohi V, Srivastava S, Basak T
Journal of Cardiovascular Development and Disease 2022
Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
Caturano A, Vetrano E, Galiero R, Salvatore T, Docimo G, Epifani R, Alfano M, Sardu C, Marfella R, Rinaldi L, Sasso FC
2022
Autocrine Signaling in Cardiac Remodeling: A Rich Source of Therapeutic Targets
VF Segers, GW Keulenaer
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2021
The Multifunctional Contribution of FGF Signaling to Cardiac Development, Homeostasis, Disease and Repair
F Khosravi, N Ahmadvand, S Bellusci, H Sauer
Frontiers in Cell and Developmental Biology 2021
FGF/FGFR signaling in health and disease
Y Xie, N Su, J Yang, Q Tan, S Huang, M Jin, Z Ni, B Zhang, D Zhang, F Luo, H Chen, X Sun, JQ Feng, H Qi, L Chen
Signal Transduction and Targeted Therapy 2020
Resveratrol and Diabetic Cardiomyopathy: Focusing on the Protective Signaling Mechanisms
YJ Song, CB Zhong, W Wu
Oxidative medicine and cellular longevity 2020
Single-cell analysis of murine fibroblasts identifies neonatal to adult switching that regulates cardiomyocyte maturation
Y Wang, F Yao, L Wang, Z Li, Z Ren, D Li, M Zhang, L Han, S Wang, B Zhou, L Wang
Nature Communications 2020
Acute Kidney Injury Sensitizes the Brain Vasculature to Ang II (Angiotensin II) Constriction via FGFBP1 (Fibroblast Growth Factor Binding Protein 1)
L Zhao, X Cao, L Li, X Wang, Q Wang, S Jiang, C Tang, S Zhou, N Xu, Y Cui, W Hu, L Fei, Z Zheng, L Chen, MO Schmidt, Q Wei, J Zhao, R Labes, A Patzak, CS Wilcox, X Fu, A Wellstein, EY Lai
Hypertension 2020
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
SJ Forrester, GW Booz, CD Sigmund, TM Coffman, T Kawai, V Rizzo, R Scalia, S Eguchi
Physiological reviews 2018
Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules
M Wolley, M Jardine, CA Hutchison
Clinical journal of the American Society of Nephrology : CJASN 2018
Calcitriol downregulates fibroblast growth factor receptor 1 through histone deacetylase activation in HL-1 atrial myocytes
TW Lee, TI Lee, YK Lin, YH Kao, YJ Chen
Journal of Biomedical Science 2018
Telocinobufagin, a Novel Cardiotonic Steroid, Promotes Renal Fibrosis via Na+/K+-ATPase Profibrotic Signaling Pathways
D Kennedy, F Khalaf, B Sheehy, M Weber, B Agatisa-Boyle, J Conic, K Hauser, C Medert, K Westfall, P Bucur, O Fedorova, A Bagrov, W Tang
International journal of molecular sciences 2018
Physiologic, Pathologic, and Therapeutic Paracrine Modulation of Cardiac Excitation-Contraction Coupling
J Mayourian, DK Ceholski, DM Gonzalez, TJ Cashman, S Sahoo, RJ Hajjar, KD Costa
Circulation research 2018
Large uremic toxins: an unsolved problem in end-stage kidney disease
MJ Wolley, CA Hutchison
Nephrology Dialysis Transplantation 2018
Triggering Endogenous Cardiac Repair and Regeneration via Extracellular Vesicle-Mediated Communication
S Bollini, AM Smits, C Balbi, E Lazzarini, P Ameri
Frontiers in physiology 2018
Fibroblast Deletion of ROCK2 Attenuates Cardiac Hypertrophy, Fibrosis, and Diastolic Dysfunction
Toru Shimizu, Nikhil Narang, Phetcharat Chen, Brian Yu, Maura Knapp, Jyothi Janardanan, John Blair, James Liao
JCI Insight 2017
Densification of Type I Collagen Matrices as a Model for Cardiac Fibrosis
LJ Worke, JE Barthold, B Seelbinder, T Novak, RP Main, SL Harbin, CP Neu
Advanced Healthcare Materials 2017
Blood Pressure Control by a Secreted FGFBP1 (Fibroblast Growth Factor–Binding Protein)Novelty and Significance
E Tassi, EY Lai, L Li, G Solis, Y Chen, WE Kietzman, PE Ray, AT Riegel, WJ Welch, CS Wilcox, A Wellstein
Hypertension 2017
Multiple faces of fibroblast growth factor-23:
X Han, LD Quarles
Current Opinion in Nephrology and Hypertension 2016
Cardiac actions of fibroblast growth factor 23
C Faul
Bone 2016
The fibrosis-cell death axis in heart failure
A Piek, RA de Boer, HH Silljé
Heart Failure Reviews 2016
The plasma membrane calcium ATPase 4 signalling in cardiac fibroblasts mediates cardiomyocyte hypertrophy
TM Mohamed, R Abou-Leisa, N Stafford, A Maqsood, M Zi, S Prehar, F Baudoin-Stanley, X Wang, L Neyses, EJ Cartwright, D Oceandy
Nature Communications 2016
Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury
SL House, AM Castro, TS Lupu, C Weinheimer, C Smith, A Kovacs, DM Ornitz
American journal of physiology. Heart and circulatory physiology 2016
Roles of FGF Signals in Heart Development, Health, and Disease
N Itoh, H Ohta, Y Nakayama, M Konishi
Frontiers in Cell and Developmental Biology 2016
Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injury
SL House, J Wang, AM Castro, C Weinheimer, A Kovacs, DM Ornitz
Physiological Reports 2015
Modulation of Cardiac Fibrosis by Kruppel-like Factor 6 through Transcriptional Control of Thrombospondin 4 in Cardiomyocytes
D Sawaki, L Hou, S Tomida, J Sun, H Zhan, K Aizawa, BK Son, T Kariya, E Takimoto, K Otsu, SJ Conway, I Manabe, I Komuro, SL Friedman, R Nagai, T Suzuki
Cardiovascular Research 2015
Protective and Therapeutic Effects of Chinese Medicine Formula Jiajian Yunvjian on Experimental Cardiac Remodeling after Myocardial Infarction Induced by Coronary Artery Ligation
J Du, W Gu, C Chen, Y Wang, J Lv
Evidence-Based Complementary and Alternative Medicine 2015
High molecular weight fibroblast growth factor-2 in the human heart is a potential target for prevention of cardiac remodeling
JJ Santiago, LJ McNaughton, N Koleini, X Ma, B Bestvater, BE Nickel, RR Fandrich, JT Wigle, DH Freed, RC Arora, E Kardami
PloS one 2014
Fibroblast growth factor receptor 1 signaling in adult cardiomyocytes increases contractility and results in a hypertrophic cardiomyopathy
SN Cilvik, JI Wang, KJ Lavine, K Uchida, A Castro, CM Gierasch, CJ Weinheimer, SL House, A Kovacs, CG Nichols, DM Ornitz
PloS one 2013
Pathophysiological roles of FGF signaling in the heart
N Itoh, H Ohta
Frontiers in physiology 2013
FGF2 modulates cardiac remodeling in an isoform- and sex-specific manner
E Nusayr, DT Sadideen, T Doetschman
Physiological Reports 2013
Cardiac development and physiology are modulated by FGF2 in an isoform- and sex-specific manner
E Nusayr, T Doetschman
Physiological Reports 2013
Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase
SL House, BE House, B Glascock, T Kimball, E Nusayr, JE Schultz, T Doetschman
Molecular and cellular pharmacology 2011
Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling
N Takeda, I Manabe
International Journal of Inflammation 2011
Changes in cardiac heparan sulfate proteoglycan expression and streptozotocin-induced diastolic dysfunction in rats
CM Strunz, M Matsuda, VM Salemi, A Nogueira, AP Mansur, IN Cestari, MV Marquezini
Cardiovascular Diabetology 2011
Intramyocardial fibroblast myocyte communication
R Kakkar, RT Lee
Circulation research 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009
Shared circuitry: developmental signaling cascades regulate both embryonic and adult coronary vasculature
KJ Lavine, DM Ornitz
Circulation research 2009
Biological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease
S Liao, J Bodmer, D Pietras, M Azhar, T Doetschman, JE Schultz
Developmental Dynamics 2008
Stemming heart failure with cardiac- or reprogrammed-stem cells
K Tateishi, N Takehara, H Matsubara, H Oh
Journal of Cellular and Molecular Medicine 2008
Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunction
D Zohlnhöfer, TG Nührenberg, F Haas, F Bengel, A Schömig, PA Baeuerle, M Schwaiger
Heart and Vessels 2008
Paracrine effects of hypoxic fibroblast-derived factors on the MPT-ROS threshold and viability of adult rat cardiac myocytes
K Shivakumar, SJ Sollott, M Sangeetha, S Sapna, B Ziman, S Wang, EG Lakatta
American journal of physiology. Heart and circulatory physiology 2008
An improved protocol for primary culture of cardiomyocyte from neonatal mice
P Sreejit, S Kumar, RS Verma
In vitro cellular & developmental biology. Animal 2008
Fibroblast Growth Factor-2 Regulates Myocardial Infarct Repair
JA Virag, ML Rolle, J Reece, S Hardouin, EO Feigl, CE Murry
The American Journal of Pathology 2007
Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies
JW Wright, S Mizutani, JW Harding
Heart Failure Reviews 2007
Connexin43-dependent mechanism modulates renin secretion and hypertension
Jacques-Antoine Haefliger, Nathalie Krattinger, David Martin, Thierry Pedrazzini, Alessandro Capponi, Britta Doering, Achim Plum, Anne Charollais, Klaus Willecke, Paolo Meda
Journal of Clinical Investigation 2006
The fibroblast growth factor-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes
Nathalie Rosenblatt-Velin, Mario Lepore, Cristina Cartoni, Friedrich Beermann, Thierry Pedrazzini
Journal of Clinical Investigation 2005
Rethinking the Renin-Angiotensin System and Its Role in Cardiovascular Regulation
P Pagliaro, C Penna
Cardiovascular Drugs and Therapy 2005
Angiotensin drives cardiac hypertrophy via transforming growth factor -beta 1
Michael Schneider
Journal of Clinical Investigation 2002

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts